WDR49

Summary

WDR49 (WD repeat domain 49, HGNC:26587) is a protein-coding gene on chromosome 3q26.1, encoding Cilia- and flagella-associated protein 337 (Q8IV35). Associates with components of the nexin-dynein regulatory complex (N-DRC), a key regulator of ciliary/flagellar motility, and might act as an inner dynein arm (IDA) hub or linkage.

This gene encodes a member of the WD repeat protein family with nine WD repeats. WD repeats are minimally conserved regions of approximately 40 amino acids typically bracketed by gly-his and trp-asp (GH-WD), which may facilitate formation of heterotrimeric or multiprotein complexes. Members of this family are involved in a variety of cellular processes, including cell cycle progression, signal transduction, apoptosis, and gene regulation. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 151790 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 119 total
• MANE Select transcript: NM_001366157

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26587
Approved symbol	WDR49
Name	WD repeat domain 49
Location	3q26.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ33620
Ensembl gene	ENSG00000174776
Ensembl biotype	protein_coding
Entrez	151790

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 12 protein_coding, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000308378, ENST00000460448, ENST00000466760, ENST00000471198, ENST00000472600, ENST00000476376, ENST00000479765, ENST00000488012, ENST00000493061, ENST00000647816, ENST00000682715, ENST00000862151, ENST00000961482, ENST00000961483, ENST00000961484

RefSeq mRNA: 4 — MANE Select: NM_001366157 NM_001348951, NM_001348952, NM_001366157, NM_001366158

CCDS: CCDS3201, CCDS93421, CCDS93422

Canonical transcript exons

ENST00000682715 — 19 exons

Exon	Start	End
ENSE00001204147	167620429	167620603
ENSE00001204149	167621467	167621643
ENSE00001204158	167626852	167627292
ENSE00001204162	167532879	167532977
ENSE00001204175	167531115	167531279
ENSE00001263757	167500153	167500299
ENSE00001263763	167505307	167505416
ENSE00001263772	167522315	167522484
ENSE00001263778	167527820	167528017
ENSE00001263783	167529052	167529239
ENSE00001703148	167554650	167554798
ENSE00001865315	167478684	167478996
ENSE00003506396	167560064	167560228
ENSE00003537480	167602127	167602275
ENSE00003634426	167575918	167576151
ENSE00003635965	167536870	167537000
ENSE00003673923	167604301	167604468
ENSE00003786012	167653261	167653499
ENSE00003835167	167653834	167653942

Expression profiles

Bgee: expression breadth ubiquitous, 163 present calls, max score 89.58.

FANTOM5 (CAGE): breadth broad, TPM avg 1.6703 / max 137.9243, expressed in 306 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
45451	1.2451	278
45452	0.2297	79
45450	0.0991	52
45449	0.0647	36
45453	0.0154	5
45454	0.0078	4
45455	0.0047	2
45456	0.0038	2

Top tissues by expression

236 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
bronchial epithelial cell	CL:0002328	89.58	gold quality
right uterine tube	UBERON:0001302	89.04	gold quality
mucosa of paranasal sinus	UBERON:0005030	88.53	gold quality
bronchus	UBERON:0002185	87.66	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	86.52	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.77	gold quality
ventricular zone	UBERON:0003053	80.84	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	78.77	gold quality
oviduct epithelium	UBERON:0004804	78.19	gold quality
epithelium of nasopharynx	UBERON:0001951	76.53	gold quality
monocyte	CL:0000576	76.12	gold quality
leukocyte	CL:0000738	75.11	gold quality
corpus callosum	UBERON:0002336	73.54	gold quality
ganglionic eminence	UBERON:0004023	72.93	gold quality
fallopian tube	UBERON:0003889	72.18	gold quality
calcaneal tendon	UBERON:0003701	72.05	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	70.48	gold quality
spinal cord	UBERON:0002240	69.35	gold quality
hypothalamus	UBERON:0001898	69.12	gold quality
right atrium auricular region	UBERON:0006631	68.67	gold quality
cardiac atrium	UBERON:0002081	67.95	gold quality
bone marrow cell	CL:0002092	66.89	gold quality
caudate nucleus	UBERON:0001873	65.72	gold quality
amygdala	UBERON:0001876	64.72	gold quality
granulocyte	CL:0000094	64.32	gold quality
nasal cavity mucosa	UBERON:0001826	64.06	gold quality
nucleus accumbens	UBERON:0001882	63.01	gold quality
substantia nigra	UBERON:0002038	62.13	gold quality
right lung	UBERON:0002167	61.09	gold quality
tendon	UBERON:0000043	60.04	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-6075	yes	88.09
E-ANND-3	yes	10.43
E-GEOD-36552	no	9.66

Regulation

Is transcription factor: no

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Wdr49	ENSMUSG00000104301
rattus_norvegicus	Wdr49	ENSRNOG00000024628

Paralogs (14): WDR54 (ENSG00000005448), FBXW11 (ENSG00000072803), FBXW7 (ENSG00000109670), TRAF7 (ENSG00000131653), FBXW9 (ENSG00000132004), FBXO36 (ENSG00000153832), WDR64 (ENSG00000162843), FBXW12 (ENSG00000164049), BTRC (ENSG00000166167), FBXW8 (ENSG00000174989), PAAF1 (ENSG00000175575), WDR86 (ENSG00000187260), FBXO16 (ENSG00000214050), EFCAB8 (ENSG00000215529)

Protein

Protein identifiers

Cilia- and flagella-associated protein 337 — Q8IV35 (reviewed: Q8IV35)

Alternative names: WD repeat-containing protein 49

All UniProt accessions (8): Q8IV35, A0A3B3IS43, C9IZ29, C9JY37, E9PDB0, F8WAZ9, H0Y8A5, H7C4Y4

UniProt curated annotations — full annotation on UniProt →

Function. Associates with components of the nexin-dynein regulatory complex (N-DRC), a key regulator of ciliary/flagellar motility, and might act as an inner dynein arm (IDA) hub or linkage.

Subunit / interactions. Associates with components of the nexin-dynein regulatory complex (N-DRC) and the CFAP184:CFAP263 complex.

Subcellular location. Cell projection. Cilium.

Similarity. Belongs to the CFAP337 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q8IV35-1	1	yes
Q8IV35-2	3
Q8IV35-3	2

RefSeq proteins (4): NP_001335880, NP_001335881, NP_001353086, NP_001353087 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001680	WD40_rpt	Repeat
IPR002048	EF_hand_dom	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR019775	WD40_repeat_CS	Conserved_site
IPR020472	WD40_PAC1	Repeat
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily
IPR051242	WD-EF-hand_domain	Family

Pfam: PF00400

UniProt features (18 total): repeat 9, splice variant 3, sequence variant 2, chain 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IV35-F1	71.92	0.27

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 38 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_UP, GSE45365_NK_CELL_VS_BCELL_DN, LHX3_01, chr3q26, TGIF_01, JAATINEN_HEMATOPOIETIC_STEM_CELL_UP, GOCC_CILIUM, DODD_NASOPHARYNGEAL_CARCINOMA_DN, SOX3_TARGET_GENES, ZIM3_TARGET_GENES, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_2, TGACAGNY_MEIS1_01, GR_Q6_01, PBX1_01, CTTTAAR_UNKNOWN

GO Biological Process (0):

GO Molecular Function (2): calcium ion binding (GO:0005509), protein binding (GO:0005515)

GO Cellular Component (2): cilium (GO:0005929), cell projection (GO:0042995)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
metal ion binding	1
binding	1
intraciliary transport particle	1
membrane-bounded organelle	1
plasma membrane bounded cell projection	1
cellular anatomical structure	1

Protein interactions and networks

STRING

286 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
WDR49	ZBBX	A8MT70	718
WDR49	TMEM253	P0C7T8	583
WDR49	GOLGA8CP	A6NN73	580
WDR49	PLEKHH3	Q7Z736	577
WDR49	LRRC74A	Q0VAA2	573
WDR49	A0A0G2JP48	A0A0G2JP48	543
WDR49	ARMCX2	Q7L311	530
WDR49	SERPINI2	O75830	514
WDR49	FAM124A	Q86V42	513
WDR49	CROCC2	H7BZ55	507
WDR49	GRIFIN	A4D1Z8	499
WDR49	IFT70A	Q86WT1	477
WDR49	ASB15	Q8WXK1	475
WDR49	PIGK	Q92643	468
WDR49	FRMD7	Q6ZUT3	465

IntAct

4 interactions, top by confidence:

A	B	Type	Score
CFAP337	ARHGAP17	psi-mi:“MI:0915”(physical association)	0.560
CFAP337	ARHGAP17	psi-mi:“MI:0914”(association)	0.560
CFAP337	HMGN2	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (4): ARHGAP17 (Affinity Capture-MS), WDR49 (Proximity Label-MS), ARHGAP17 (Affinity Capture-MS), L3MBTL1 (Affinity Capture-MS)

ESM2 similar proteins: A0JMR6, A2RRS8, A6NFN9, A8MPX8, B1ANS9, O15297, O75747, P25022, P79457, Q08AW4, Q14680, Q14AW5, Q15052, Q2IBB1, Q2IBB4, Q2IBG0, Q2QL84, Q2QLH1, Q3MJ13, Q3US16, Q4R3G4, Q4R7Q1, Q5H913, Q5JTW2, Q5R5T0, Q5R6E1, Q5RFQ4, Q5SUS0, Q5XGI3, Q5XX13, Q5XXR3, Q692V3, Q6P2S7, Q6P3V7, Q7XVF9, Q86VS3, Q8BVT6, Q8C0W1, Q8C5W4, Q8IV35

Diamond homologs: A0JMQ0, A1CJY4, A1D3F5, A1D7I5, A2QEV8, A3LX18, A4RDD7, A5DGL8, A5DVY3, A6RUL1, A6ZMK5, A7EF03, A7RM20, A7TH19, A8ID74, A8QBF3, A8WVX8, B0BNA7, B0WC36, B0XFT7, B0XYC8, B3MHX6, B3MVL6, B3N4C7, B3NLK7, B4GIU9, B4GSH1, B4HN85, B4I195, B4J9K1, B4JB43, B4KGX9, B4KQU8, B4LKS9, B4LUA5, B4MYI5, B4N0L0, B4NW98, B4P528, B4Q354

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

119 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	97
Likely benign	11
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

4087 predictions. Top by Δscore:

Variant	Effect	Δscore
3:167531275:TGTAT:T	acceptor_gain	1.0000
3:167531277:TAT:T	acceptor_gain	1.0000
3:167531279:TC:T	acceptor_loss	1.0000
3:167531280:C:CC	acceptor_gain	1.0000
3:167531281:T:G	acceptor_loss	1.0000
3:167532974:CTCC:C	acceptor_gain	1.0000
3:167560228:CCTAA:C	acceptor_loss	1.0000
3:167560229:C:CA	acceptor_loss	1.0000
3:167560230:T:C	acceptor_loss	1.0000
3:167566828:A:AC	donor_gain	1.0000
3:167566829:C:CA	donor_gain	1.0000
3:167602276:C:CC	acceptor_gain	1.0000
3:167602281:C:CT	acceptor_gain	1.0000
3:167602282:A:T	acceptor_gain	1.0000
3:167602286:T:TC	acceptor_gain	1.0000
3:167604469:C:CC	acceptor_gain	1.0000
3:167482067:CAAA:C	donor_gain	0.9900
3:167482068:AAAA:A	donor_gain	0.9900
3:167500151:A:AC	donor_gain	0.9900
3:167500152:C:CC	donor_gain	0.9900
3:167500317:T:C	acceptor_gain	0.9900
3:167500317:T:TC	acceptor_gain	0.9900
3:167531109:TTTTA:T	donor_loss	0.9900
3:167531110:TTTA:T	donor_loss	0.9900
3:167531111:TTAC:T	donor_loss	0.9900
3:167531112:TAC:T	donor_loss	0.9900
3:167531114:C:A	donor_loss	0.9900
3:167531114:CCTG:C	donor_gain	0.9900
3:167531276:GTAT:G	acceptor_gain	0.9900
3:167531278:AT:A	acceptor_gain	0.9900

AlphaMissense

6982 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:167602142:G:C	S79R	0.996
3:167602142:G:T	S79R	0.996
3:167602144:T:G	S79R	0.996
3:167560220:G:C	S165R	0.994
3:167560220:G:T	S165R	0.994
3:167560222:T:G	S165R	0.994
3:167576139:A:G	W89R	0.989
3:167576139:A:T	W89R	0.989
3:167602243:A:G	W46R	0.982
3:167602243:A:T	W46R	0.982
3:167602275:G:T	A35E	0.981
3:167532951:A:G	W309R	0.978
3:167532951:A:T	W309R	0.978
3:167529063:A:G	W447R	0.976
3:167529063:A:T	W447R	0.976
3:167602245:A:G	L45P	0.975
3:167529200:A:T	V401D	0.974
3:167576137:C:A	W89C	0.974
3:167576137:C:G	W89C	0.974
3:167602176:A:T	V68D	0.974
3:167575966:G:C	S146R	0.973
3:167575966:G:T	S146R	0.973
3:167575968:T:G	S146R	0.973
3:167536942:A:G	W276R	0.971
3:167536942:A:T	W276R	0.971
3:167532973:A:C	S301R	0.969
3:167532973:A:T	S301R	0.969
3:167532975:T:G	S301R	0.969
3:167602149:A:G	L77P	0.969
3:167529098:A:G	L435P	0.968

dbSNP variants (sampled 300 via entrez): RS1000025944 (3:167492938 G>A), RS1000047162 (3:167548856 C>A), RS1000059337 (3:167586676 C>T), RS1000094262 (3:167648910 TAC>T), RS1000116825 (3:167499432 T>G), RS1000134126 (3:167563138 G>A), RS1000141713 (3:167513457 G>A), RS1000155933 (3:167556130 C>A), RS1000173610 (3:167580352 C>G), RS1000219835 (3:167612143 C>A,G,T), RS1000221105 (3:167530781 G>T), RS1000264784 (3:167550170 A>G), RS1000268248 (3:167580012 G>C,T), RS1000285656 (3:167569151 C>T), RS1000295813 (3:167506113 C>G)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST001525_6	Visceral fat	2.000000e-06
GCST004048_1	Fast beta electroencephalogram	5.000000e-09
GCST004599_84	Mean platelet volume	6.000000e-19
GCST010135_19	Oily fish consumption	3.000000e-10
GCST010136_12	Fruit consumption	1.000000e-08
GCST010140_11	Pork consumption	3.000000e-10
GCST010142_12	Fish- and plant-related diet	1.000000e-11
GCST010796_1427	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08
GCST90002395_394	Mean platelet volume	8.000000e-55

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004357	electroencephalogram measurement
EFO:0008111	diet measurement
EFO:0004327	electrocardiography

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

12 total (human), top 12 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
graphene oxide	increases expression	1
licochalcone B	increases expression	1
Air Pollutants	increases abundance, increases expression	1
Arsenic	affects methylation	1
Cadmium	decreases expression, increases abundance	1
Smoke	increases abundance, increases expression	1
Thimerosal	increases expression	1
Tobacco Smoke Pollution	affects expression	1
Aflatoxin B1	increases methylation	1
Antirheumatic Agents	decreases expression	1
Cadmium Chloride	increases abundance, decreases expression	1
Okadaic Acid	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer